The Dividend Harvesting Portfolio hit new all-time highs in value, profitability, and forward income, with a 29.58% return on invested capital. Consistent weekly investing, diversification, and a focus on income-producing assets have driven strong performance, even through volatile markets and macroeconomic headwinds. I see significant opportunities ahead, especially for big tech, REITs, and energy stocks, as the Fed's delayed rate cuts create a favorable environment.
Bristol Myers Squibb is undervalued despite the looming patent cliff, as its robust pipeline and strong cash flow position it for future growth. The impact of Eliquis' patent expiry is overstated, since only half its revenue affects BMY's bottom line due to the Pfizer partnership. Earnings have been depressed by past acquisition amortizations, but these charges will drop sharply, revealing stronger profitability.
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $47.66, denoting a +1.32% move from the preceding trading day.
![]() BRM 1 weeks ago | Other | €0.53 Per Share |
![]() BRM 3 months ago | Other | €0.53 Per Share |
![]() BRM 6 months ago | Other | €0.53 Per Share |
![]() BRM 9 months ago | Other | €0.51 Per Share |
![]() BRM 5 Jul 2024 | Other | €0.51 Per Share |
31 Jul 2025 (In 2 weeks) Date | | 1.35 Cons. EPS | - EPS |
25 Apr 2025 Date | | - Cons. EPS | - EPS |
24 Apr 2025 Date | | - Cons. EPS | - EPS |
6 Feb 2025 Date | | - Cons. EPS | - EPS |
31 Oct 2024 Date | | - Cons. EPS | - EPS |
![]() BRM 1 weeks ago | Other | €0.53 Per Share |
![]() BRM 3 months ago | Other | €0.53 Per Share |
![]() BRM 6 months ago | Other | €0.53 Per Share |
![]() BRM 9 months ago | Other | €0.51 Per Share |
![]() BRM 5 Jul 2024 | Other | €0.51 Per Share |
31 Jul 2025 (In 2 weeks) Date | | 1.35 Cons. EPS | - EPS |
25 Apr 2025 Date | | - Cons. EPS | - EPS |
24 Apr 2025 Date | | - Cons. EPS | - EPS |
6 Feb 2025 Date | | - Cons. EPS | - EPS |
31 Oct 2024 Date | | - Cons. EPS | - EPS |
Drug Manufacturers - General Industry | Healthcare Sector | Christopher S. Boerner CEO | XMUN Exchange | US1101221083 ISIN |
US Country | 34,100 Employees | 3 Jul 2025 Last Dividend | 7 Aug 2001 Last Split | - IPO Date |
Bristol-Myers Squibb Company is an eminent global biopharmaceutical firm engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of innovative biopharmaceutical products. With a spectrum of treatments covering hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases, the company has established a significant footprint in the healthcare sector. Initially founded as Bristol-Myers Company in 1887, it has evolved over the decades to become a leader in the biopharmaceutical industry, headquartered in Princeton, New Jersey. The company's operational reach spans globally, selling products through a diversified channel mix including wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.